CATEGORIES: Research
Rare Neurological Disease Special Report

HNF Featured in Rare Neurological Disease Special Report

by | Apr 9, 2019 | 0 comments

rare neurological disease special report

The Hereditary Neuropathy Foundation is proud to announce that for the fifth year in a row, we have been featured in the annual Rare Neurological Disease Special Report—a widely-read supplement included in the mailing of the March issues of Neurology Reviews. It is also distributed at all major neurology conferences throughout the year, including the 2019 MDA Clinical and Scientific Conference in Orlando, Florida April 13th-17th. If you attend come visit HNF at the Neurology Reviews booth.

We are diligently educating neurologists and Health Care Providers about CMT on your behalf.

Neurology Reviews is the first and original news source in neurology and has a history of providing independent, unbiased news to neurologists and clinicians interested in the neurosciences.

Here is what HNF featured in the March, 2019 edition: 

  • HNF ad “What is CMT?” page 10

  • “FDA Hears the CMT Community Voice Loud and Clear on September 28, 2018” page 11

  • “CMT1A and Impaired Patient Mobility: Expressions, Remedies, and Impact of Quality of Life” page 12

  • HNF’s Industry Partners Pharnext & Acceleron page 35 & 36

  • HNF’s Research Partner Dr. Stephen Züchner page 38-41

  • PSA Genetic Testing Awareness for Neurologists page 80

As with all of HNF’s programs, we rely on donations and support from our industry sponsors, government grants and YOU! Please donate today to support our continued medical outreach initiatives.

DONATE TODAY!

Learn more on this topic

Related Blog Posts

Hot Off the Press – Potential Treatment for CMT1A

by | Mar 9, 2015 | , , | 53 Comments

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

by | Mar 9, 2015 | , | 0 Comments

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

by | Sep 16, 2014 | , | 2 Comments

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

by | Aug 19, 2014 | , , | 1 Comment

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

by | Jul 7, 2014 | | 4 Comments

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

by | May 19, 2014 | | 0 Comments

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

by | Feb 28, 2014 | | 0 Comments

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

by | Feb 12, 2014 | | 5 Comments

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news